Best medication for Psoriasis, honestly

The strongest topical class (class I) and the standard starter for limited plaque psoriasis — plaques flatten within days to two weeks. Labeling limits use to 2 consecutive weeks and no more than 50 g (or 50 mL) per week, because prolonged use over large areas can suppress the adrenal (HPA) axis. No FDA boxed warning. Skin thinning is a label warning and usually improves over months after stopping; stretch marks (striae) and telangiectasias are effectively permanent. Rebound flare after stopping a prolonged course abruptly is a well-described clinical effect, though it is not itself in the labeling — taper under direction rather than quitting cold. Not for the face, groin, or underarms, and not under occlusion (bandages, plastic wrap, diapers) unless a clinician directs it. Not recommended under age 12 — children absorb proportionally more and are at higher risk of adrenal suppression, Cushing's syndrome and growth suppression. Impoyz is a 0.025% clobetasol cream: a lower concentration, but still a clobetasol product carrying the same short-course limits and adrenal-suppression warnings, not a milder alternative.

Steroid-free, so it can be used long-term for maintenance where clobetasol cannot. Slower — expect 4-8 weeks for full effect — and commonly paired with or alternated with a topical steroid, which also reduces the irritation calcipotriene can cause. No boxed warning. The main safety limit is how much body area you treat: calcipotriene is contraindicated if you already have high blood calcium or vitamin D toxicity, raised blood calcium has been reported, and the label directs that it not be used on the face. (The 100 g per week cap people cite belongs to the calcipotriene-plus-steroid combinations such as Taclonex, not to calcipotriene alone.) Sorilux is the foam formulation, often chosen for the scalp. Do not mix calcipotriene with salicylic acid products, which inactivate it.

An oral pill approved for adults with plaque psoriasis who are candidates for phototherapy or systemic therapy, and for active psoriatic arthritis. Its practical distinction: it is not a biologic, its label requires no TB screening and no routine bloodwork, and it carries no boxed warning — which makes it an oral choice for people who want a systemic drug without injections. It is better described as an immunomodulator than a broad immunosuppressant. The trade-off is efficacy: it clears skin less completely than the biologics below. Diarrhea and nausea are common in the first weeks (the pack starts with a dose titration for this reason) and the label directs dose reduction or suspension if diarrhea, nausea or vomiting become severe. Label warnings also include depression and new suicidal thoughts, and weight decrease — weight should be monitored regularly. Dose is reduced in severe kidney impairment.

Self-injected, typically 80 mg to start, then 40 mg every other week beginning one week after that first dose. Carries an FDA BOXED WARNING for SERIOUS INFECTIONS — including tuberculosis (often reactivated latent TB), invasive fungal infections, and other opportunistic infections — and for MALIGNANCY, including lymphoma; hepatosplenic T-cell lymphoma, usually fatal, has been reported mainly in adolescents and young adults treated for inflammatory bowel disease. Test for latent TB before the first dose and treat it first. Beyond the boxed warning, the label warns about new or worsening heart failure, about new onset or exacerbation of demyelinating disease such as multiple sclerosis or optic neuritis, and about hepatitis B reactivation — HBV carriers must be monitored during and for several months after therapy, so hepatitis B status is checked alongside TB before starting. Despite all this, TNF blockers remain a mainstay because they treat skin and joints and have decades of use data; they are often required first by insurers.

Among the highest skin-clearance rates available for plaque psoriasis, with the most convenient schedule: 150 mg at week 0, week 4, then once every 12 weeks. No boxed warning. Main label cautions are infection risk and the pre-treatment tuberculosis evaluation required of all biologics; hepatitis B screening before starting is standard dermatology practice (it is a labeled warning for the TNF blocker Humira, not for this drug), and live vaccines should be avoided during treatment. Guselkumab (Tremfya) is the same class on an every-8-week schedule after loading. IL-23 agents post some of the highest clearance rates in head-to-head trials and are a common choice when skin is the dominant problem — but for SKIN disease the AAD/NPF guidance does not designate a preferred first-line biologic class, and comorbidities and insurance usually decide. For joint disease it differs — ACR/NPF conditionally recommends TNF inhibitors first in treatment-naive active psoriatic arthritis.

Fast — many people improve substantially by 4-8 weeks, helped by the weekly loading doses through week 4. Dosed 300 mg at weeks 0, 1, 2, 3 and 4, then every 4 weeks; some patients are maintained on 150 mg. No boxed warning. Two class-specific issues matter: IL-17 blockade can cause or worsen inflammatory bowel disease, so it is generally avoided if you have Crohn's disease or ulcerative colitis, and candida (yeast) infections of the mouth or skin are more common. The label directs evaluating for tuberculosis before starting, and hepatitis B reactivation has been reported with secukinumab and the label advises against use in active viral hepatitis, so hepatitis B status is checked beforehand. Anaphylaxis and angioedema have been reported and previous serious hypersensitivity to secukinumab is a contraindication. Severe eczematous eruptions have been reported with IL-17 blockers and can require stopping the drug. Ixekizumab (Taltz) is the same class with a similar profile.

Taken ONCE WEEKLY, not daily — the FDA BOXED WARNING states that inadvertent once-daily administration has resulted in death. The same boxed warning covers embryo-fetal toxicity including fetal death (methotrexate is contraindicated in pregnancy for non-cancer indications such as psoriasis), severe hypersensitivity including anaphylaxis, and serious adverse reactions including death affecting the bone marrow, gastrointestinal tract, liver, lungs, skin and kidneys — which is why baseline and ongoing blood counts, liver tests and kidney function are required. Interactions matter as much as dose: aspirin and other NSAIDs, sulfonamide antibiotics such as trimethoprim/sulfamethoxazole (Bactrim), other antifolate drugs, proton pump inhibitors, penicillins and probenecid all raise methotrexate exposure and the risk of severe toxicity. Do not add any new medicine, including over-the-counter ibuprofen or naproxen, without telling the prescriber. Alcohol and hepatotoxic drugs raise liver risk. Its FDA indication in dermatology is severe psoriasis; it is NOT FDA-approved for psoriatic arthritis, though it is widely used for joint symptoms. Folic acid supplementation is standard to reduce side effects. Full benefit takes roughly 8-12 weeks. Contraindications differ by product, which matters because this page covers both forms: the subcutaneous psoriasis autoinjectors (Otrexup, Rasuvo) are CONTRAINDICATED in alcoholism, alcoholic or other chronic liver disease, immunodeficiency syndromes, and preexisting blood dyscrasias such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anemia — these are absolute bars, not cautions — in addition to pregnancy and severe hypersensitivity. The newer oral tablet labels list only pregnancy and severe hypersensitivity in Contraindications, though the same risks appear there under Warnings and Precautions.

The longest-established of the interleukin-targeting biologics (approved 2009), predating the IL-17 and IL-23 agents. Dosed by weight (45 mg or 90 mg) at week 0, week 4, then every 12 weeks. No boxed warning. Requires the same pre-treatment tuberculosis evaluation, with hepatitis B status checked as for other biologics, and carries infection and malignancy cautions; live vaccines should be avoided. Rare but serious label warnings include posterior reversible encephalopathy syndrome (PRES) — get urgent care for headache with seizures, confusion or vision change — serious hypersensitivity including anaphylaxis and angioedema, and noninfectious pneumonia. Newer IL-23-only agents generally clear skin more completely, so Stelara is often chosen for its track record, dosing interval, or formulary position rather than maximum efficacy.

Steroid-free and useful for thick, stubborn plaques; it is also used off-label for nail psoriasis, where the evidence is limited to small studies. CONTRAINDICATED IN PREGNANCY — the label states retinoids may cause fetal harm. This is a Contraindication plus Warnings and Precautions 5.1 on the current FDA label; there is no boxed warning, despite what many summaries claim. Pregnancy must be excluded before starting and effective contraception used during treatment. The gel is indicated for plaque psoriasis of up to 20% body surface area, and its safety above that has not been established. Expect burning, stinging, and peeling early on; clinicians often pair it with a topical steroid to blunt the irritation. Works over weeks, not days.